Lupos Biotechnology Inc

Medical

Genelux Corporation | September 29, 2021

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Medical

PR Newswire | October 05, 2023

Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx's gene therapies ...

Labiotech.eu | January 27, 2020

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Medical

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...